Bavarian Nordic A/S (BVNKF)

Market Cap	1.85B
Revenue (ttm)	793.54M
Net Income (ttm)	137.15M
Shares Out	n/a
EPS (ttm)	1.75
PE Ratio	13.52
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	108
Average Volume	135
Open	23.37
Previous Close	24.23
Day's Range	23.37 - 24.23
52-Week Range	18.72 - 46.05
Beta	1.68
RSI	50.81
Earnings Date	Mar 5, 2025

About Bavarian Nordic

Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV for the treatment of encephalitis viruses. It operates in the Unite...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1992
• Employees: 1,605
• Stock Exchange: OTCMKTS
• Ticker Symbol: BVNKF

Financial Performance

In 2024, Bavarian Nordic's revenue was 5.72 billion, a decrease of -19.06% compared to the previous year's 7.06 billion. Earnings were 987.98 million, a decrease of -33.03%.

Financial numbers in DKK